Antibodies specific for LOX1 and use in treatment of cardiovascular disorders
This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.
MedImmune Limited
A C A C C C C C G C C C C C C A C C C C A A C A C A C C C G C
A61K C12N A61K C07K C07K C07K C07K C12N G01N C12N C12N C07K C07K C07K C07K A61P C12N C12N C12N C07K A61K A61K C12N A61P C07K A61P C12N C07K C07K G01N C07K
additional additional additional inventional additional additional inventional additional additional inventional inventional additional additional additional additional inventional additional additional additional additional inventional inventional additional inventional inventional inventional inventional additional additional additional additional
Matthieu Daniel E. Deepesh Andrew Clare Johanna Lewis H. Fumin Peter
Chodorge Berkowitz Pandey Buchanan Balendran Husmark Romer Chang Cariuk